The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Acceleron Pharma Inc. | COM | 00434H108 | 4,036 | 162,070 | SH | SOLE | 162,070 | 0 | 0 | ||
| BioDelivery Sciences International, Inc. | COM | 09060J106 | 2,749 | 494,468 | SH | SOLE | 494,468 | 0 | 0 | ||
| Orexigen Therapeutics, Inc. | COM | 686164104 | 2,594 | 1,229,287 | SH | SOLE | 1,229,287 | 0 | 0 | ||